{"nctId":"NCT00617851","briefTitle":"Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old","startDateStruct":{"date":"2007-11"},"conditions":["Influenza"],"count":1507,"armGroups":[{"label":"Influenza virus vaccine (lot A)","type":"EXPERIMENTAL","interventionNames":["Biological: Lot A of Influenza virus vaccine"]},{"label":"Influenza virus vaccine (lot B)","type":"EXPERIMENTAL","interventionNames":["Biological: Lot B of Influenza virus vaccine"]},{"label":"Influenza virus vaccine (lot C)","type":"EXPERIMENTAL","interventionNames":["Biological: Lot C of Influenza virus vaccine"]},{"label":"Influenza virus vaccine (pooled)","type":"EXPERIMENTAL","interventionNames":["Biological: All 3 consecutive lots of influenza virus vaccine pooled"]},{"label":"Comparator influenza vaccine","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator influenza virus vaccine"]}],"interventions":[{"name":"Lot A of Influenza virus vaccine","otherNames":[]},{"name":"Lot B of Influenza virus vaccine","otherNames":[]},{"name":"Lot C of Influenza virus vaccine","otherNames":[]},{"name":"Comparator influenza virus vaccine","otherNames":[]},{"name":"All 3 consecutive lots of influenza virus vaccine pooled","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 to 49 years of age;\n* In good health as determined by medical history and physical examination;\n* Able and willing to provide written informed consent prior to any study procedure;\n* Able to comply with all study procedures and available for all clinic visits scheduled in the study.\n\nExclusion Criteria:\n\n* Any serious disease, such as: cancer, autoimmune disease (including rheumatoid arthritis), advanced arteriosclerotic disease or complicated diabetes mellitus\n* History of any anaphylaxis, serious vaccine reactions, or hypersensitivity to eggs, egg protein, chicken feathers, influenza viral protein, neomycin, polymyxin, or any other vaccine component, chemically related substance, or component of the potential packaging materials (latex);\n* Known or suspected impairment/alteration of immune function\n* Receipt of an influenza vaccine within 6 months prior to Visit 1;\n* Current drug or alcohol abuse or a history of drug or alcohol abuse that in the investigator's opinion would interfere with safety of the subject or the evaluation of the study objectives;\n* Laboratory-confirmed influenza disease within 6 months prior to Visit 1","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs), by Vaccine Lots","description":"The immunologic equivalence of three consecutive production lots of the influenza virus vaccine was measured in terms of GMTs for all vaccine influenza strains.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"566","spread":null},{"groupId":"OG001","value":"518","spread":null},{"groupId":"OG002","value":"513","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"352","spread":null},{"groupId":"OG001","value":"313","spread":null},{"groupId":"OG002","value":"359","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"93","spread":null},{"groupId":"OG002","value":"86","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs), by Vaccine Group and Strain","description":"The GMTs and 95% CIs were calculated for each of the vaccine group (three consecutive production lots pooled for the investigational influenza virus vaccine and comparator) and for each strain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"532","spread":null},{"groupId":"OG001","value":"341","spread":null},{"groupId":"OG002","value":"93","spread":null},{"groupId":"OG003","value":"799","spread":null},{"groupId":"OG004","value":"683","spread":null},{"groupId":"OG005","value":"99","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Local and Systemic Symptoms","description":"Solicited local and systemic reactions were assessed after vaccination for the two vaccines (three consecutive production lots pooled for the investigational influenza virus vaccine and comparator) and for each of the three consecutive production lots of the investigational influenza virus vaccine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"310","spread":null},{"groupId":"OG004","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"44","spread":null},{"groupId":"OG004","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"62","spread":null},{"groupId":"OG004","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"53","spread":null},{"groupId":"OG004","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"41","spread":null},{"groupId":"OG004","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"87","spread":null},{"groupId":"OG002","value":"85","spread":null},{"groupId":"OG003","value":"268","spread":null},{"groupId":"OG004","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null},{"groupId":"OG001","value":"148","spread":null},{"groupId":"OG002","value":"147","spread":null},{"groupId":"OG003","value":"443","spread":null},{"groupId":"OG004","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"29","spread":null},{"groupId":"OG003","value":"87","spread":null},{"groupId":"OG004","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"144","spread":null},{"groupId":"OG004","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"65","spread":null},{"groupId":"OG003","value":"213","spread":null},{"groupId":"OG004","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"25","spread":null},{"groupId":"OG003","value":"69","spread":null},{"groupId":"OG004","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"292","spread":null},{"groupId":"OG004","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"48","spread":null},{"groupId":"OG004","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"41","spread":null},{"groupId":"OG003","value":"111","spread":null},{"groupId":"OG004","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"54","spread":null},{"groupId":"OG004","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With at Least One Unsolicited Adverse Event","description":"Number of subjects reporting at least one unsolicited adverse event, regardless of the assessement of relatedness to the study vaccines (each of the three consecutive production lots of the investigational influenza virus vaccine, the pooled influenza virus vaccine, and the comparator influenza vaccine).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"56","spread":null},{"groupId":"OG003","value":"68","spread":null},{"groupId":"OG004","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Seroprotection and Seroconversion (Strain A/H1N1)","description":"The percentage of subjects who were seroprotected and seroconverted were considered statistically compliant with the stated CBER guidance criteria if:\n\n* the lower bound of the two-sided 95% CI for the percentage of seroprotected subjects (HI antibody titer ≥1:40) met or exceeded 70%.\n* the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconversion rate (prevaccination HI\\<10/ postvaccination HI ≥40 or at least a fourfold increase in titer from non-negative prevaccination serum \\[HI≥10\\]), for HI antibody met or exceeded 40%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"99","spread":null},{"groupId":"OG002","value":"98","spread":null},{"groupId":"OG003","value":"98","spread":null},{"groupId":"OG004","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"93","spread":null},{"groupId":"OG003","value":"94","spread":null},{"groupId":"OG004","value":"96","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Seroprotection and Seroconversion (Strain A/H3N2)","description":"The percentage of subjects who were seroprotected and seroconverted were considered statistically compliant with the stated CBER guidance criteria if:\n\n* the lower bound of the two-sided 95% CI for the percentage of seroprotected subjects (HI antibody titer ≥1:40) met or exceeded 70%.\n* the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconversion rate (prevaccination HI\\<10/ postvaccination HI ≥40 or at least a fourfold increase in titer from non-negative prevaccination serum \\[HI≥10\\]), for HI antibody met or exceeded 40%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"99","spread":null},{"groupId":"OG003","value":"99","spread":null},{"groupId":"OG004","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"68","spread":null},{"groupId":"OG003","value":"67","spread":null},{"groupId":"OG004","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Seroprotection and Seroconversion (Strain B)","description":"The percentage of subjects who were seroprotected and seroconverted were considered statistically compliant with the stated CBER guidance criteria if:\n\n* the lower bound of the two-sided 95% CI for the percentage of seroprotected subjects (HI antibody titer ≥1:40) met or exceeded 70%.\n* the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconversion rate (prevaccination HI\\<10/ postvaccination HI ≥40 or at least a fourfold increase in titer from non-negative prevaccination serum \\[HI≥10\\]), for HI antibody met or exceeded 40%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"88","spread":null},{"groupId":"OG002","value":"84","spread":null},{"groupId":"OG003","value":"87","spread":null},{"groupId":"OG004","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"81","spread":null},{"groupId":"OG003","value":"84","spread":null},{"groupId":"OG004","value":"86","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":1209},"commonTop":[]}}}